Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases

BACKGROUND: Leptomeningeal metastases (LM) are devastating complications of epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). Although osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI), has better penetration into the central nervous system than f...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, K., Yoshida, T., Masuda, K., Matsumoto, Y., Shinno, Y., Okuma, Y., Goto, Y., Horinouchi, H., Yamamoto, N., Ohe, Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485398/
https://www.ncbi.nlm.nih.gov/pubmed/37517364
http://dx.doi.org/10.1016/j.esmoop.2023.101594

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485398/
https://www.ncbi.nlm.nih.gov/pubmed/37517364
http://dx.doi.org/10.1016/j.esmoop.2023.101594

Ejemplares similares